Greenwich LifeSciences, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $228.2M
- Price
- $16.67
- % Change (Daily % change from the live per-ticker quote feed.)
- +8.61%
- Volume
- 176.8K
About
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.
Quick stats
Shares outstanding14.7M
Computed float6.3M
Float / shares43.2%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001799788
AI Summary
AI-generated1/20
standardbullishother
Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027
Greenwich LifeSciences extended the lock-up period for shares held by directors, officers, and pre-IPO investors to January 31, 2027, approximately 76 months from the company's IPO.
While the board retains discretion to modify the lock-up for strategic transactions, the move limits near-term selling pressure and aligns insider interests with long-term value creation.
CEO Snehal Patel provided a clinical update, noting that the Phase III FLAMINGO-01 trial has more than doubled its enrollment and event rates, with over 1,500 patients screened across up to 200 sites.